Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Core Viewpoint - Immunovant, Inc. is set to host an investor webcast to discuss results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from its Phase 2b study in chronic inflammatory demyelinating polyneuropathy (CIDP) [1] Group 1 - The investor webcast will take place on March 19th at 8:00 a.m. ET [1][3] - The call will feature Immunovant's CEO Pete Salzmann and Roivant's CEO Matt Gline [2] - A replay of the event and presentation will be available immediately after the live webcast [3] Group 2 - Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases [4] - The company specializes in anti-FcRn technology to create targeted therapies for complex autoimmune conditions [4]